Evidence map›Paper›PMID 42207223›Full record

ArticleInternal and emergency medicine2026

Global, regional, and national burden of chronic obstructive pulmonary disease and asthma from 1990 to present: risk attributions and projections to 2050.

Wendi Zhang, Zenghou Liu, Xiaoxin Wang, Yanhua Wang, Cuixia Zhang, Yanwei Wang, Yan Tong, Bo Song, Xin Zhao, Xin Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. AARS1-Mediated RUNX3 K193 Lactylation Enhances the Activation and Cytotoxicity of CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wendi Zhang *Central Laboratory, Yantai Yuhuangding Hospital, Yantai, 264000, China.
Zenghou Liu *School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, China.
Xiaoxin Wang *Central Laboratory, Yantai Yuhuangding Hospital, Yantai, 264000, China.
Yanhua WangDepartment of Medical Records Room, Weifang People's Hospital, Weifang, 261000, China.
Cuixia ZhangDepartment of Medical Records Room, Weifang People's Hospital, Weifang, 261000, China.
Yanwei WangCentral Laboratory, Yantai Yuhuangding Hospital, Yantai, 264000, China.
Yan TongCenter for Reproductive Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, 330001, China.
Bo SongDepartment of Infection Management Control, Yantai Yuhuangding Hospital, Yantai, 264000, China. bosong78@163.com.
Xin ZhaoDepartment of Transfusion Medicine, Yantai Yuhuangding Hospital, Yantai, 264000, China. zx8002@126.com.
Xin LiuCentral Laboratory, Yantai Yuhuangding Hospital, Yantai, 264000, China. dkgha@163.com.ORCID http://orcid.org/0000-0001-8143-457X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Chronic obstructive pulmonary disease (COPD) and asthma constitute two major global public health challenges with substantial societal and health system impacts. However, large-scale, long-term comparative studies on their epidemiological patterns and risk factor contributions remain scarce. This study aimed to systematically evaluate the global, regional, and national burden and temporal trends of COPD and asthma from 1990 to 2021, with further projections to 2050. Methods Data from 21 regions and 204 countries and territories were obtained from the Global Burden of Disease and Risk Factors Study 2021, covering the period 1990-2021. We quantified prevalence, mortality, disability-adjusted life years (DALYs), and risk factor attribution for COPD and asthma. Burden trends were subsequently projected through 2050 using predictive modeling. Results From 1990 to 2021, the global epidemiological trajectories of COPD and asthma diverged markedly. While the absolute number of prevalent COPD cases more than doubled (from 100.54 to 213.38 million), its age-standardized prevalence rate remained stable, and both age-standardized mortality and DALY rates fell substantially (by 37.45% and 37.0%, respectively). In contrast, asthma exhibited declines across all metrics: incident cases decreased by 8.90%, and age-standardized prevalence, mortality, and DALY rates dropped by 40.01%, 46.06%, and 44.46%, respectively. The burden was inequitably distributed: COPD incidence and prevalence were highest in low-middle Socio-demographic Index (SDI) regions, whereas asthma prevalence peaked in high-SDI regions, with its highest mortality in low SDI settings. Smoking remained the leading global risk factor for COPD DALYs, but household air pollution dominated in low SDI regions. For asthma, high body mass index emerged as the primary risk factor. Sex disparities were clear: COPD burden was higher in males, while asthma predominantly affected females in adulthood. Projections to 2050 indicate a continued rise in absolute COPD case numbers alongside declining age-standardized rates, whereas asthma burdens are forecast to decline in both absolute and rate terms. Conclusions Despite significant improvements in age-standardized rates of mortality and disability, the absolute burden of COPD has grown tremendously, driven by demographic forces. Asthma shows more favorable trends. The stark disparities in burden and risk factors underscore the need for dual strategies: global efforts to control risk factors (tobacco, air pollution, obesity) must be coupled with targeted measures to strengthen healthcare access in under-resourced settings and advance precision medicine for complex disease phenotypes.

Indexed as

AsthmaCOPDEpidemiologyRisk factorsSociodemographic index

Identifiers

PMID42207223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.